External carotid artery to middle cerebral artery bypass with the saphenous vein graft

Erica F Bisson1, Agostino J Visioni, Bruce Tranmer

  • 1Division of Neurosurgery, Department of Surgery, University of Vermont College of Medicine, Burlington, Vermont, USA.

Neurosurgery
|April 25, 2008
PubMed

Insights

For patients with severe cerebrovascular disease unresponsive to standard treatments, extracranial-intracranial bypass using a saphenous vein graft offers a viable alternative when typical grafts are insufficient. This technique provides a high-flow conduit for complex cases.

Area of Science:

  • Neurosurgery
  • Vascular Surgery
  • Cerebrovascular Medicine

Background:

  • Occlusive cerebrovascular disease poses significant risks, especially when maximal medical therapy and standard surgical interventions fail.
  • Identifying suitable bypass conduits is crucial for patients requiring extracranial-intracranial bypass.
  • The superficial temporal artery is a common graft vessel, but its inadequacy necessitates alternative solutions.

Purpose of the Study:

  • To detail the technical aspects of performing an extracranial-intracranial bypass using a saphenous vein graft.
  • To present the saphenous vein as a viable alternative conduit for high-flow bypass in specific patient populations.

Main Methods:

  • Focus on the technical considerations for saphenous vein graft harvesting and preparation.
  • Describe the surgical steps involved in creating an extracranial-intracranial bypass with a saphenous vein graft.

Main Results:

  • The saphenous vein can serve as an effective high-flow conduit when the superficial temporal artery is inadequate.
  • Successful implementation of saphenous vein grafts in extracranial-intracranial bypass procedures is technically feasible.

Conclusions:

  • Saphenous vein grafts are a valuable option for extracranial-intracranial bypass in selected patients with occlusive cerebrovascular disease.
  • This technique expands treatment possibilities for complex cerebrovascular conditions unresponsive to conventional therapies.